<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) frequently <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasizes</z:e> to the liver, a phenomenon that involves the participation of transforming-growth-factor-β(1) (TGFβ(1)) </plain></SENT>
<SENT sid="1" pm="."><plain>Blockade of the protumorigenic effects elicited by TGFβ(1) in advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> could attenuate <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We aimed in the present study to assess the antimetastatic effect of TGFβ(1)-blocking <z:chebi fb="7" ids="16670">peptides</z:chebi> P17 and P144, and to study mechanisms responsible for this activity in a mouse model </plain></SENT>
<SENT sid="3" pm="."><plain><z:mp ids='MP_0009314'>Colon adenocarcinoma</z:mp> cells expressing luciferase were pretreated with TGFβ(1) (Mc38-luc(TGFβ1) cells), injected into the spleen of mice and monitored for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development </plain></SENT>
<SENT sid="4" pm="."><plain>TGFβ(1) increased <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> growth and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e>, whereas systemic treatment of mice with either P17 or P144 significantly reduced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden (p&lt;0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>In metastatic nodules, mitotic/apoptotic ratio, mesenchymal traits and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> (evaluated by CD-31, as well as circulating endothelial and progenitor cells) induced by TGFβ(1) were consistently reduced following injection of <z:chebi fb="7" ids="16670">peptides</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>In vitro experiments revealed a direct effect of TGFβ(1) in Mc38 cells, which resulted in activation of Smad2, Smad3 and Smad1/5/8, and increased invasion and transendothelial migration, whereas blockade of TGFβ(1)-signaling reverted these features </plain></SENT>
<SENT sid="7" pm="."><plain>Because TGFβ(1)-mediated epithelial-mesenchymal transition (EMT) has been suggested to induce a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cell (<z:chebi fb="11" ids="17437,53115">CSC</z:chebi>) phenotype, we analyzed the ability of this cytokine to induce tumorsphere formation and the expression of <z:chebi fb="11" ids="17437,53115">CSC</z:chebi> markers </plain></SENT>
<SENT sid="8" pm="."><plain>In TGFβ(1)-treated cells, tumorspheres were enriched in CD44 and SOX2, which were diminished in the presence of P17 </plain></SENT>
<SENT sid="9" pm="."><plain>Our data provide a preclinical rationale to evaluate P17 and P144 as potential therapeutic options for the treatment of metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>